Alliancebernstein L.P. Has $170.30 Million Stake in Pfizer Inc. $PFE

Alliancebernstein L.P. raised its stake in Pfizer Inc. (NYSE:PFE) by 0.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 6,683,481 shares of the biopharmaceutical company’s stock after acquiring an additional 54,536 shares during the period. Alliancebernstein L.P. owned about 0.12% of Pfizer worth $170,295,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Grey Fox Wealth Advisors LLC bought a new position in Pfizer during the 3rd quarter valued at about $29,000. Howard Hughes Medical Institute bought a new stake in Pfizer during the second quarter worth about $30,000. Darwin Wealth Management LLC acquired a new stake in shares of Pfizer during the second quarter worth approximately $32,000. Evelyn Partners Asset Management Ltd acquired a new stake in shares of Pfizer during the second quarter worth approximately $33,000. Finally, True Wealth Design LLC raised its stake in shares of Pfizer by 302.5% in the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 974 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on PFE shares. UBS Group began coverage on Pfizer in a research report on Tuesday, January 6th. They set a “neutral” rating and a $25.00 price target on the stock. TD Cowen reiterated a “hold” rating on shares of Pfizer in a research report on Tuesday, December 30th. HSBC reissued a “buy” rating and issued a $29.00 price objective on shares of Pfizer in a research note on Wednesday, December 10th. Daiwa Securities Group cut Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price on the stock. in a report on Thursday, February 12th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $30.00 price target on shares of Pfizer in a report on Monday, March 9th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, fourteen have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, Pfizer has a consensus rating of “Hold” and a consensus target price of $28.05.

Pfizer Stock Performance

Shares of Pfizer stock opened at $26.61 on Tuesday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. The firm has a 50 day simple moving average of $26.53 and a 200 day simple moving average of $25.54. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.94. The firm has a market cap of $151.28 billion, a P/E ratio of 19.56 and a beta of 0.47.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.09. The firm had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The business’s revenue for the quarter was down 1.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.63 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.